| Autor: |
Oganov RG, Kiseleva NG, Aronov DM, Akhmedzhanov NM, Olfer'ev AM, Kiseleva NS, Perova NV |
| Jazyk: |
ruština |
| Zdroj: |
Kardiologiia [Kardiologiia] 1993; Vol. 33 (10), pp. 54-9, 6. |
| Abstrakt: |
The hypolipidemic effects of induracin, a new long-acting nicotinic acid dosage form based on the waxy matrix, and its tolerance were studied in 31 patients with Types IIa and IIb hyperlipoproteinemias in a 6-month blind crossover study. There were decreases in the levels of total cholesterol by 9-13% and low density lipoprotein cholesterol by 12-22%, an increase in high density lipoprotein cholesterol by 12-15%, and a good dynamics in the ratio of blood lipid-transport proteins--a 12-16% increase to the levels of apoprotein AI to a 29% decrease in those of apoprotein B. The drug is well tolerated by patients and may be recommended for correction of atherogenic dyslipidemias. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
